Showing results (31-40 of 84) with videos related to
Sort By:
Pageof 9
Journal of Hepatology|February 22, 2011
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver diseaseEric Trépo, Thierry Gustot, Delphine Degré, et al.Human Molecular Genetics|September 21, 2007
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseasesVinciane Dideberg, Gudlaug Kristjansdottir, Lili Milani, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2015
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's DiseaseGeert D'Haens, Mark Löwenberg, Mark A Samaan, et al.Plos Genetics|April 10, 2025
The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease riskClaire Liefferinckx, David Stern, Hélène Perée, et al.Journal of Hepatology|April 6, 2013
Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver diseaseEric Trépo, Romy Ouziel, Pierre Pradat, et al.Inflammatory Bowel Diseases|February 2, 2017
Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel DiseasesSubrata Ghosh, Edouard Louis, Laurent Beaugerie, et al.Gastroenterology|February 26, 2026
The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE studyPeter Bossuyt, Jean-Francois Rahier, Filip Baert, et al.Journal of Crohn'S & Colitis|October 4, 2018
Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With VedolizumabAnnick Moens, Karen van Hoeve, Evelien Humblet, et al.United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2019
Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and DysplasiaAnneline Cremer, Pieter Demetter, Martine De Vos, et al.Pageof 9